Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug
  Response
  Transfer learning has been shown to be effective in many applications in
which training data for the target problem are limited but data for a related
(source) problem are abundant. In this paper, we apply transfer learning to the
prediction of anti-cancer drug response. Previous transfer learning studies for
drug response prediction focused on building models that predict the response
of tumor cells to a specific drug treatment. We target the more challenging
task of building general prediction models that can make predictions for both
new tumor cells and new drugs. We apply the classic transfer learning framework
that trains a prediction model on the source dataset and refines it on the
target dataset, and extends the framework through ensemble. The ensemble
transfer learning pipeline is implemented using LightGBM and two deep neural
network (DNN) models with different architectures. Uniquely, we investigate its
power for three application settings including drug repurposing, precision
oncology, and new drug development, through different data partition schemes in
cross-validation. We test the proposed ensemble transfer learning on benchmark
in vitro drug screening datasets, taking one dataset as the source domain and
another dataset as the target domain. The analysis results demonstrate the
benefit of applying ensemble transfer learning for predicting anti-cancer drug
response in all three applications with both LightGBM and DNN models. Compared
between the different prediction models, a DNN model with two subnetworks for
the inputs of tumor features and drug features separately outperforms LightGBM
and the other DNN model that concatenates tumor features and drug features for
input in the drug repurposing and precision oncology applications. In the more
challenging application of new drug development, LightGBM performs better than
the other two DNN models.
